Corneal endothelial (CE) cells do not divide in vivo, leading to edema, corneal clouding and vision loss when the density drops below a critical level. The endothelium can be replaced by transplanting allogeneic tissue; however, access to donated tissue is limited worldwide resulting in critical need for new sources of corneal grafts. In vitro expansion of CE cells is a potential solution, but is challenging due to limited proliferation and loss of phenotype in vitro via endothelial to mesenchymal transformation (EMT) and senescence. We hypothesized that a bioengineered substrate recapitulating chemo-mechanical properties of Descemet's membrane would improve the in vitro expansion of CE cells while maintaining phenotype. Results show that bovine CE cells cultured on a polydimethylsiloxane surface with elastic modulus of 50 kPa and collagen IV coating achieved >3000-fold expansion. Cells grew in higher-density monolayers with polygonal morphology and ZO-1 localization at cell-cell junctions in contrast to control cells on polystyrene that lost these phenotypic markers coupled with increased α-smooth muscle actin expression and fibronectin fibril assembly. In total, these results demonstrate that a biomimetic substrate presenting native basement membrane ECM proteins and mechanical environment may be a key element in bioengineering functional CE layers for potential therapeutic applications.
The corneal endothelium (CE) forms a monolayer on the posterior surface of the cornea that actively pumps water from the corneal stroma into the aqueous humor1,2. At birth the human CE contains ~5,000 cells/mm2, but the cells are mitotically inactive and as a result cell density decreases throughout life3,4. There is a rapid, non-linear decrease in cell density from the second trimester to ages 2–10, most likely due to the increase in the size of the cornea, followed by a slower, linear decrease in cell density due to cell aging and death5,6. When CE damage, disease, or aging causes cell density to drop below ~500 cells/mm2, the CE can no longer pump enough water to compensate for diffusion into the cornea, resulting in stromal edema, corneal clouding and eventual vision loss7. Transplantation of donor CE tissue, either as a full-thickness penetrating keratoplasty (PK) or as one of the several forms of endothelial keratoplasty, can restore CE function and corneal transparency8,9,10,11. While successful, rejection and recurrence of CE cell loss remain common complications of these whole tissue/organ grafts12,13,14,15,16. Further, these grafts require use of donated cadaveric tissue, which in many parts of the world is limited in availability or is entirely non-existent14,16. Thus, there remains a critical need for new therapies to repair, regenerate or replace the CE in order to reverse corneal edema and restore normal vision.
Currently, endothelial grafts constitute a 1:1 replacement of CE tissue with that of a cadaveric cornea. The number of such grafts produced by each donor eye could be increased significantly if CE cells were expanded in culture before grafting. Such an approach requires the ability to expand CE cells in a manner that maintains physiological CE function and a compatible carrier on which to transplant an engineered CE monolayer. Historically, cultured adult CE cells have been observed to undergo one or two population doublings in vitro, but rapidly become senescent or undergo endothelial to mesenchymal transition (EMT) to a fibroblastic phenotype17,18,19. A number of studies have optimized culture media formulation15 and supplemented with growth factors such as FGF2, EGF and NGF1,20 to stimulate CEC growth. Additionally, the use of extracts from bovine corneal endothelial cells21,or small molecules such as Rho kinase inhibitor Y2763222,23,24 and ascorbic acid 2 phosphate25,26 have been used to expand CE cells. Still other studies have investigated improving CE cell isolation27,28,29,30,31, using various extracellular matrix (ECM) proteins to improve CE cell attachment27,32,33,34 and immortalizing the CE cells with the SV40 T-antigen30,31. All of these approaches have resulted in some measurable improvement in CE cell expansion in vitro, but none have achieved satisfactory results. Reproducibility, senescence and EMT after expansion in vitro continue to pose significant barriers to generating enough CE cells for therapeutic applications.
Here we have focused on the microenvironment of the CE cells, specifically the chemical and mechanical properties, as a means to increase proliferation and maintain phenotype. Researchers have shown that interaction with the ECM controls cell cycle entry, differentiation and function for a variety cell types35,36,37,38. These cell-matrix interactions largely result from integrin binding to specific amino acid motifs in the ECM proteins and the signaling resulting from them is strongly influenced by the mechanical and topological properties of the matrix35,36,37,38. In the current study we hypothesized that expansion of CE cells in a manner that maintains phenotype is dependent on the mechanical and biochemical properties of the substrate. To test this we first screened a range of substrate elastic moduli and ECM protein coatings spanning from the standard tissue culture-treated polystyrene (TCPS) to softer substrates similar to Descemet's membrane to ultra-soft substrates. Bovine CE cells were used because we could obtain 25–50 age matched 1–2 year-old eyes at one time to get the number of cells required for large screening studies, which was not possible using human tissue. After identifying a substrate that best preserved CE phenotype, we then evaluated the ability of this substrate to also improve in vitro expansion. The results presented here will demonstrate that engineering a biomimetic substrate with mechanical and ECM properties similar to Descemet's membrane provides a microenvironment that promotes both the expansion and normal phenotype of bovine CE cells during extended in vitro culture. This is important, because it shows the ability to use physical and insoluble chemical cues to expand bovine CE cells, which could provide a potential pathway for generating large numbers of human CE cells for future therapeutic applications.
CE Cells Cultured on a Rigid Substrate Acquire an Abnormal Morphology
Cells in a native CE layer exhibit a distinctive morphology consisting of regular, hexagonal cells densely packed in a continuous monolayer20,39,40,41. This morphology is common across species, including that of the bovine corneas used in this study (Fig. 1a). The tight junction protein zona occludens 1 (ZO-1) formed a near-continuous band at cell-cell junctions and immediately interior to the ZO-1 staining, F-actin was organized into a thin cortical layer. No actin stress fibers were observed to traverse the cell bodies. In contrast, CE cells grown on standard cell culture surfaces such as glass coverslips (Fig. 1b) or TCPS (Fig. 1c) were characterized by lower cell density, irregular morphology, punctate and discontinuous ZO-1 at the cell-cell borders and F-actin organized into a much thicker cortical cytoskeleton that extended many micrometers in from the cell border. This aberrant CE morphology was observed from the first passage of CE cells on rigid surfaces and became more pronounced through successive passages. Using the CE morphology as a metric, our goal was to engineer a substrate that supported CE growth and monolayer formation such that the morphology of the cells more closely resembled that observed in the intact endothelium.
Screening of Substrate Biochemical and Mechanical Properties to Determine the Effect on CE Morphology
We hypothesized that matching the mechanical and biochemical properties of the native Descemet's membrane would aid in maintaining a differentiated phenotype of cultured CE cells. This was tested using a 36-condition screen to systematically vary substrate elastic modulus and ECM protein surface coating. To do this we used a tunable polydimethylsiloxane (PDMS) elastomer system to engineer substrates with six different elastic moduli (5, 50, 130, 830, 1340 or 1720 kPa)42 that were used as-is or were coated with the ECM proteins fibronectin, laminin 111, collagen type I, collagen type IV, or a blend of laminin and collagen type IV (see Supplementary Fig. S1 online). Each substrate condition was seeded with passage 2 (P2) bovine CE cells that had been expanded from isolation on TCPS. As shown in Fig. 2, representative images stained for F-actin and ZO-1 revealed marked differences as a function of substrate properties after 7 days in culture. Cell-density was similar on the various substrates, but on the stiffer PDMS formulations (E ≥ 830 kPa), F-actin was most often observed in a thick cortical cytoskeleton with internal stress fibers and minimal ZO-1 present at the cell-cell junctions. The exception to this was on substrates coated with collagen IV, all of which exhibited similar polygonal morphology, ZO-1 at cell borders and F-actin located cortically. Substrates with lower elastic moduli induced variable cell morphologies depending on the protein coating. For example, fibronectin and collagen I coated surfaces showed poor CE phenotype for all of elastic modulus, again with with reduced ZO-1 and non-cortical F-actin fibers. In contrast, laminin and laminin/collagen IV surfaces showed a general decrease in non-cortical F-actin fibers and increase in ZO-1 at the cell borders as elastic modulus decreased from 1.7 MPa to 50 kPa. Unexpectedly, CE cells on the softest substrate (E = 5 kPa), appeared similar to stiffer substrates, demonstrating that the substrate could be too soft to support the desired morphology. Finally, CE cells on uncoated PDMS (i.e., coated only with ECM proteins adsorbed from the FBS in the media) did exhibit an in vivo-like morphology in some conditions, but the cells divided very slowly, taking a long time to reach confluence. After a qualitative analysis of all 36 conditions, we determined that the best phenotypic expression of continuous ZO-1 at the cell-cell border and a thin, cortical F-actin cytoskeleton occurred for CE cells on the PDMS with the collagen type IV protein coating and an elastic modulus of 50 kPa, which we termed PDMS50+COL4. Because this is similar to the reported composition and elastic modulus of Descemet's membrane, we also referred to this specific PDMS50+COL4 substrate as biomimetic8,43,44.
Enhancement of CE Cell Proliferation on the Biomimetic PDMS Substrate
Next, we asked whether the PDMS50+COL4 biomimetic substrate could maintain differentiated CE cells in a normal phenotype while enhancing proliferation during long-term culture. To test this we compared four different substrate conditions; TCPS as a standard control, TCPS coated with collagen type IV (TCPSCOL4) to evaluate the effect of the ECM protein coating, PDMS with elastic modulus of 50 kPa but no protein to evaluate the effect of substrate stiffness (PDMS50) and PDMS50+COL4. Long-term culture was performed for up to 10 passages, with the primary harvested CE cells seeded directly on and contacting only the specific substrate indicated (see Supplementary Fig. S2 online). The same number of CE cells was seeded onto each substrate at P0 and then split 1:3 at each subsequent passage. We did not control for cell density after P0 because we wanted to determine on which substrate CE cells could most rapidly expand using standard serial passaging techniques. From the outset, CE cells cultured on PDMS50 grew very slowly and failed to reach confluence by day 30, thus this condition was not further evaluated (data not shown). Representative phase-contrast images (Fig. 3a) show that CE cell morphology and cell density varied substantially from P1 to P10 for cells on TCPS, TCPSCOL4 and PDMS50+COL4. Qualitatively, CE cells at P1 on all three substrates exhibited a normal polygonal morphology; however, cells on TCPS were larger than those on TCPSCOL4 and PDMS50+COL4. By P5, CE cells on TCPS and TCPSCOL4 had adopted an enlarged and polarized morphology and at P8 were even further enlarged with irregular shapes, enlarged nuclei and fibroblast-like morphology. In distinct contrast, CE cells on PDMS50+COL4 at P5 and P8 maintained a higher cell density and a polygonal morphology characteristic of CE cells. At P10, CE cells on all the substrates had lost their characteristic polygonal morphology, suggesting that even on the biomimetic substrate there is a limit to how long CE cell phenotype can be maintained over extended passages in vitro.
We next used image analysis to quantify CE cell density, growth rate and average cell size as a function of substrate condition and passage number. CE cell density (Fig. 3b, see statistical analysis in Supplementary Table S1 online) was normalized relative to the cell density on TCPS at P0 on a per harvest basis. At all passages CE cells on PDMS50+COL4 were at significantly greater density (~50%) than on TCPS, demonstrating that the biomimetic substrate improved proliferation. It is important to note that TCPSCOL4 had cell densities in between that of PDMS50+COL4 and TCPS, suggesting that the ECM protein had some effect. However, this effect decreased over time, with cell denisty on PDMS50+COL4 greater than on both TCPS and TCPSCOL4 from P4 through P10. Plotting cell proliferation as a function of time showed that CE cells on the PDMS50+COL4 had a >3,000-fold increase in cell number while maintaining a polgonal morphology up to P8 (Fig. 3c). This was more than an order-of-magnitude greater than the increase in cell number on TCPS and TCPSCOL4, which expanded only 139- and 138-fold respectively and had already adopted a polarized morphology prior to P5 (Fig. 3c). Finally, we quanitifed average cell size at confluence on the different substrates as a function of passage number (Fig. 3d, see statistical analysis in Supplementary Table S2 online). While CE cell size was larger than that observed in the intract endothelium on all substrates, the CE cells cultured on the PDMS50+COL4 were smallest in size relative to TCPS and TCPSCOL4 at all passages. In total, these results demonstrate that the PDMS50+COL4 substrate supported higher cell densities, greater proliferation rates and smaller cell size relative to the TCPS control and TCPSCOL4 substrates.
CE Cell Phenotype is Maintained on the Biomimetic PDMS Substrate
Having established that the PDMS50+COL4 substrate enhanced proliferation, we next investigated whether CE phenotype was maintained. The phase-contrast images (Fig. 3a) suggested that the CE cells on PDMS50+COL4 remained differentiated with normal morphology, but to confirm this we stained for a variety of specific protein markers. The tight junction protein ZO-1 revealed that on the biomimetic PDMS50+COL4 substrate CE junctional integrity was maintained at P1 and P5 with near continuous staining at the cell-cell borders (Fig. 4a), similar to that observed in the intact endothelium (Fig. 1a). On TCPS, little contiguous ZO-1 staining was observed in any of the cultures (Fig. 4a). Addition of collagen IV to TCPS did have an apparent effect, enabling some ZO-1 junctions to form at P1; however, by P5 the staining showed discontinuous regions (Fig. 4a). These results demonstrate that PDMS50+COL4 allows the CE cells to maintain continuous areas of tight junctions and do so over an increased number of population doublings as compared to rigid TCPS controls.
The ability to maintain differentiated CE cells longer in culture on the PDMS50+COL4 suggested that the substrate was able to inhibit dedifferentiation or transformation relative to TCPS and TCPSCOL4. For example, after corneal damage CE cells in vivo can undergo EMT, becoming motile, fibroblastic and forming a fibrous retrocorneal membrane containing the proteins fibronectin, collagen I, α-smooth muscle actin and vimentin. A similar EMT-like transformation occurs to CE cells in vitro in response to serum and growth factors45. To understand why EMT appeared to be reduced for CE cells on the PDMS50+COL4 substrate, we first examined the ECM proteins being assembled at the cell/substrate interface. Collagen type IV was stained using antibodies and was present up to P8 on the PDMS50+COL4 and TCPSCOL4 pre-coated with the protein, but absent on the uncoated TCPS control (data not shown). This provided little insight and simply indicated that the collagen type IV remained at the interface when pre-coated. Next, we stained for fibronectin, which is assembled by cells into fibrils and is characteristic of CE cells undergoing EMT in vivo46. By P1 CE cells on TCPS had organized the fibronectin into a fibrillar ECM network that became more pronounced by P5 (Fig. 4a). CE cells on TCPSCOL4 also assembled a fibrillar fibronectin matrix, though the effect was less pronounced with fibrils appearing shorter and less organized. In contrast, fibronectin assembled by CE cells on PDMS50+COL4 remained diffuse and at most developed into small, punctate-like fibrils (Fig. 4a). This lack of fibronectin fibrillar matrix formation indicated a distinct difference in how CE cells on the PDMS50+COL4 were behaving in terms of matrix assembly.
We next looked at the cytoskeleton and cell shape to further analyze differential cell responses. CE cells undergoing EMT are known to assemble robust actin cytoskeletons that are positive for α-smooth muscle actin (α-SMA)47,48,49,50,51. At P1 CE cells on the three substrates exhibited very little α-SMA by immunofluorescent staining (Fig. 4b). However, by P5, CE cells on the TCPS and the TCPSCOL4 had more frequent α-SMA positive cells, which appeared to be larger and had robust actin filament staining across the cell bodies (Fig. 4b). Quantification of the percent α-SMA positive cells (Fig. 4c) revealed that even at P1 a significantly greater number of cells on TCPS expressed this protein compared to PDMS50+COL4. By P5 the percentage of α-SMA positive cells on TCPS and TCPSCOL4 were both greater than PDMS50+COL4 (Fig. 4c, see statistical analysis in Supplementary Table S3 online). It should be noted that even though the percentage of α-SMA positive cells on TCPS was only ~1%, this was still two orders-of-magnitude greater than on PDMS50+COL4. Finally, we used morphometric image analysis to determine whether the polygonal CE cells were able to reform a hexagonal morphology, similar to that observed in the intact endothelium (as seen in Fig. 1a). Here again results showed that CE cells on PDMS50+COL4 had a hexagon shape factor (HSF) that more closely matched that of CE cells in the intact endothelium in the ex vivo tissue (Fig. 4d, see statistical analysis in Supplementary Table S4 online). The HSF for CE cells on PDMS50+COL4 was significantly lower than on both TCPS and TCPSCOL4 at P1 and P5. This result, in combination with the increased ZO-1 staining and decreased fibronectin fibrillar matrix formation strongly suggests that CE cells on the PDMS50+COL4 have more well-developed cell-cell interactions as compared to CE cells on TCPS and TCPSCOL4.
CE Cells Expanded on the Biomimetic PDMS Substrate form Higher Density Engineered Tissues
The ability to expand CE cells on the PDMS50+COL4 substrate provides the opportunity to generate large quantities of cells for therapeutic applications. As a first step to evaluate this potential, we tested the ability of the expanded CE cells to tissue engineer a corneal endothelium using a carrier substrate suitable for implantation. To do this we first cultured CE cells on TCPS, TCPSCOL4 or PDMS50+COL4 until P5 and then seeded 300,000 CE cells onto each 15 μm thick, 20 mm diameter collagen type I gel, to approximate the corneal stroma. After 24 hours in culture it was observed that CE cells expanded on PDMS50+COL4 and then cultured on the collagen gel were growing at a higher density and were nearly confluent with a polygonal morphology. In contrast, CE cells expanded on TCPS and TCPSCOL4 and then cultured on the collagen gel were sub-confluent and had a polarized morphology (Fig. 5a). After 48 hours in culture, immunofluorescent labeling revealed that CE cells expanded on all three substrates were confluent, but those initially expanded on TCPS and TCPSCOL4 had decreased ZO-1 at the cell-cell border and frequent actin filaments that traversed the cell body (Fig. 5a). In contrast, CE cells expanded on PDMS50+COL4 had many regions where ZO-1 was continuously stained at the cell-cell border along with actin filaments localized primarily to the cell periphery. CE cells expanded on PDMS50+COL4 also formed a significantly higher density monolayer (1528 ± 143 cells/mm2) compared to those formed by cells expanded on TCPS (921 ± 157 cells/mm2) and TCPSCOL4 (1122 ± 168 cells/mm2) (Fig. 5b, see statistical analysis in Supplementary Table S5 online). These results demonstrate that CE cells expanded on the PDMS50+COL4 have the potential to form an endothelium with 40% - 50% higher density than CE cells expanded on the TCPS and TCPSCOL4 surfaces, establishing that the culture history of these cells is import even when the cells are subsequently seeded on a collagen type I gel scaffold.
Our results demonstrate that the biomimetic PDMS substrate we developed enables CE cells to be expanded >3,000-fold in vitro while maintaining a range of phenotypic markers characteristic of differentiated endothelium. This is more than an order-of-magnitude increase in the cell expansion as compared to the TCPS and TCPSCOL4 and other quantitative metrics including cell density, cell size, α-SMA expression and HSF were also all improved on the PDMS50+COL4. While we used a 36-condition screen to identify the PDMS50+COL4 substrate, it turns out that the combination of an elastic modulus of 50 kPa and collagen type IV coating is similar to the native Descemet's membrane upon which CE cells adhere to in vivo43,44. While in hindsight it might seem obvious that mimicking Descemet's membrane would work, the body of literature to date has described a broad range of soluble and insoluble molecules used to improve the culture of CE cells. For example, CE cells have been expanded with varying degrees of success on surface immobilized collagen type I34, collagen type IV34, laminin33,34, FNC1,18,34 and fibronectin32,34. Other approaches have focused on soluble factors added to culture media such as bFGF, EGF and NGF20, the addition of extracts from bovine corneal endothelial cells21, ROCK inhibitor Y2763222,23,24, ascorbic acid 2 phosphate25,26 and TGF-β inhibitor SB43154252; the use viral transfections30,31 or reprogramming of the cells to neural crest progenitor cells17,53,54. For example, Zhu et al showed that knockdown of p120 Catenin and Kaiso promoted an ~15-fold expansion of human CE cells while maintaining a cell density of >2,000 cells/mm253. What is unique about our approach is the incorporation of substrate mechanics as an additional factor, which in combination with the collagen type IV coating provides a simple system to expand CE cells that relies solely on microenvironmental factors, i.e. mechanical and biochemical properties of the substrate, in order to induce cell proliferation. This allows us to use a very minimal media containing only the basal DMEM media, serum and antibiotics without the need for additional growth factors, small molecules or genetic alterations to the CE cells during expansion.
The primary question raised by our results is why the PDMS50+COL4 achieved improved results compared to the TCPS and TCPSCOL4 controls. The data clearly shows that relatively speaking, the TCPS and TCPSCOL4 substrates promoted CE cell EMT while the PDMS50+COL4 substrate inhibited it. This assessment is supported by the fact that CE cells cultured on PDMS50+COL4 had significantly smaller cell areas and HSF as compared to controls and more robust ZO-1 staining and cortical actin at all time points. This apparent increase in cell-cell adhesion and lack of spreading on PDMS50+COL4 is important, because EMT is characterized by cell polarization and loss of the polygonal morphology, which is inhibited when cells are in a densely packed monolayer45. There are a wide range of markers for EMT including the morphological markers already mentioned as well as expression of transcription factors such as Snail, Slug and Twist50. Here we selected expression of α-SMA in the cytoskeleton throughout the cell as a definitive marker of EMT in endothelial cells that have transformed into fibroblasts. The CE cells expressing α-SMA were readily identified by their robust expression and at P5 α-SMA positive cells had actin stress fibers throughout the cells, especially noticeable on the TCPS (P1 and P5) and TCPSCOL4 (Fig. 4b). The percentage of α-SMA positive CE cells on TCPS (P1 and P5) and TCPSCOL4 (P5) was significantly greater than on PDMS50+COL4 (Fig. 4c), confirming relative inhibition of EMT on the biomimetic substrate. The expression of α-SMA is considered a relatively mature marker of EMT and thus it is likely that a larger percentage of CE cells have progressed to some intermediate state of EMT50. The fact that the CE cells on TCPSCOL4 are different by most metrics compared to PDMS50+COL4 indicates that the collagen type IV coating is not solely responsible for the inhibition of EMT. Rather, the data suggests that the difference is also due to the lower elastic modulus of the PDMS50+COL4. Imaging of the fibronectin matrix assembled by CE cells on the different substrates revealed that the soft PDMS50+COL4 had a pronounced effect by preventing large fibril formation (Fig. 4a). It is known that substrates with elastic modulus in the 10's of kiloPascal range inhibit stress fiber and focal adhesion formation relative to stiffer substrates36,37 and that stress fibers and the resulting cell contractility increase fibronectin matrix assembly55. Further, recent reports have demonstrated that integrin-mediated TGFβ activation and EMT is increased on stiff fibronectin coated surfaces as compared to softer surfaces due to the increased cell contractility56. This provides an explanation for why the PDMS50+COL4 is better at inhibiting EMT relative to the controls, that the soft PDMS50+COL4 inhibits actin stress fiber formation, which limits contractility and fibronectin fibrillar matrix assembly and which in turn reduces integrin-mediated TGFβ activation and EMT.
The variable quality of corneal donor tissue and the limited availability of donor corneas outside the US highlight the need to develop a tissue engineered endothelium suitable for implantation. Many studies use one donor cornea to create one tissue engineered CE, which does not address the need for an increase in the availability of CE monolayers for transplant. The PDMS50+COL4 developed here is a potential solution to this problem, providing a substrate on which to expand enough CE cells to engineer multiple tissues from a single donor. To evaluate whether this is possible, we performed proof-of-concept experiments using a thin, collagen type I gel as a substrate for engineering a freestanding endothelium. Results showed that P5 cells expanded on PDMS50+COL4 could form a dense monolayer with polygonal cells that expressed ZO-1 at the cell-cell borders and cortical F-actin. The CE cell density on the PDMS50+COL4 was higher than on the controls, which is important because this should improve the pump function of the tissue. While we did not implant this tissue in this study to test function in vivo, the results do show that CE cells expanded on PDMS50+COL4 generate a larger total number of cells and that they form higher density monolayers with improved expression of phenotypic markers. For implantation we would also want to further increase CE cell density to >1,500 cells/mm2, which should be achievable by increasing cell seeding density. Future work will examine whether the biomimetic PDMS50+COL4 validated here using bovine CE cells is also effective for expanding human CE cells. Note that we used bovine cells in these experiments because they provided a consistent and reproducible source of cells for the 36-condition substrate screen and expansion studies. Bovine corneas are larger than human and we could obtain 25–50 age matched 1–2 year-old eyes at one time to get the number of cells required. Further, we will also investigate whether there is a synergistic effect by combining the PDMS50+COL4 surface with soluble factors such as ROCK inhibitor, Y-2763224 and TGF-β inhibitor, SB43154252, which have also been shown to increase the proliferative capacity of CE cells in vitro. Finally, we plan to test the engineered corneal endothelium on the collagen type I gel carrier (Fig. 5) in an in vivo animal model in order to determine whether the pump function is maintained in the expanded cells. Studies with human CE cells will be far more challenging due to limited supply and cost of donor tissue, donor to donor variability, the small number of CE cells that can be recovered from each cornea and the potential need to further optimize the biomimetic PDMS substrate for species-specific differences.
CE Cell Isolation and Culture
Bovine CE cells were isolated from fresh whole bovine eyes (Pel-Freez Biologicals, Rogers AR, USA). The corneas were excised from whole globes and soaked for 20 minutes in PBS containing 1% penicillin/streptomycin/amphotericin B and 0.5% gentamicin. Corneas were incubated endothelial side up in a 12-well spot plate with approximately 300 μL of TrypLE Express at 37°C for 20 minutes. CE cells were released into the TrypLE Express by gently scraping with a rubber scalpel, combined and centrifuged for 5 minutes at 1500 rpm. The cells were designated as passage 0 (P0), resuspended in low glucose DMEM with 10% FBS, 1% penicillin/streptomycin/amphotericin B and 0.5% gentamicin and cultured in standard TCPS flasks or flasks coated with PDMS and/or collagen type IV depending on the experiment.
Screening of Substrate Biochemical and Mechanical Properties
To perform the substrate screen we used six different elastic modulus PDMS formulations, which were prepared according to previously published methods42. Briefly, Sylgard 184 PDMS elastomer and Sylgard 527 PDMS gel were prepared separately according to the manufacturer's specifications. Sylgard 184 (E = 1720 kPa) was prepared by mixing 10 parts base with 1 part curing agent (10:1) for 2 minutes at 2,000 RPM in a Thinky Cup Conditioning mixer followed by a defoaming cycle of 2 minutes at 2000 RPM. Sylgard 527 (E = 5 kPa) was prepared by mixing equal weights of part A and part B (1:1) for 2 minutes at 2,000 RPM followed by defoaming at 2000 RPM for two minutes. The intermediate elastic modulus PDMS formulations were prepared by mixing Sylgard 184 and Sylgard 527 in defined mass ratios of 5:1 (E = 1.34 MPa), 1:1 (E = 830 kPa), 1:5 (E = 130 kPa) and 1:10 (E = 50 kPa). For these PDMS blends, the Sylgard 184 and 527 were weighed and combined together using an additional mixing and defoaming cycle. All six PDMS formulations were spin coated onto 25 mm diameter glass coverslips at 4,000 RPM to create ~15 μm thick films followed by curing at 60°C for 8 hours. Coverslips were treated in a UV-Ozone cleaner for 15 minutes and used as-is or coated with either 50 μg/mL FN (human plasma, BD Biosciences, San Jose, CA, USA), 100 μg/mL collagen type I (rat tail Sigma-Aldrich CO, St. Louis, MO, USA)., 50 μg/mL laminin (Engelbreth-Holm-Swarm mouse tumor, BD Biosciences), 50 μg/mL collagen type IV (human placenta, Sigma-Aldrich), a mixture of 50 μg/mL laminin or 50 μg/mL collagen type IV in distilled deionized water for one hour at room temperature. Uncoated controls and ECM protein coated samples were rinsed three times in phosphate buffered saline (PBS) before cell culture experiments. Coverslips were seeded with 300,000 bovine CE cells (P2) and monitored for cell growth and morphology over a 7 day period using phase contrast microscopy. On day 7, all samples were fixed, stained and imaged using confocal microscopy.
Long-term Culture and Expansion of CE Cells
The four different substrates used in the expansion experiments were TCPS, TCPSCOL4, PDMS50 and PDMS50+COL4. To prepare TCPSCOL4, a T-25 flask was coated with 5 mL of 50 μg/mL collagen type IV for one hour at room temperature, rinsed once and stored with 5 mL of ddH2O inside until use. The PDMS50 was prepared by coating T-25 flasks with a ~0.5 mm thick layer of the 50 kPa elastic modulus PDMS formulation and cured at 60°C for 24 hours. The PDMS50+COL4 was prepared as described for the PDMS50 followed by UV-ozone treatment and coated with collagen type IV as described for the TCPSCOL4. All flasks were used within 3 days of protein coating. Bovine CE cells from 30–50 corneas were isolated as described above, pooled and seeded evenly on to the four substrates described above (note: 10 corneas per surface to be seeded were used in each trial). CE cells were cultured until confluent and serial passaged 1:3 until passage 10. Briefly, at each passage the confluent cells from each substrate were released using TrypLE Express, centrifuged and resuspended in 6 mL of culture media. Next, 2 mL of the cell suspension was seeded in to a new flask, 2 mL was frozen and the final 2 mL was seeded onto PDMS50+COL4 coated coverslips or TCPS controls for staining and imaging. Four trials were performed from separate cell isolations resulting in TCPS (n = 4), TCPSCOL4 (n = 5) and PDMS50+COL4 (n = 5) flasks (all trials had at least one flask of each type, the final trial had two each of the TCPSCOL4 and PDMS50+COL4 flasks). CE cells seeded onto PDMS50 at P0 failed to reach confluence after 30 days and therefore were not used in further experiments. Cell morphology and confluence were monitored daily using a Nikon TS100 phase contrast microscope equipped with a Nikon D7000 camera. Cell density at confluence was calculated using the phase contrast images and the multi-point selection tool in ImageJ. To enable direct comparison of the different cell isolations (where the number of cells and cell viability can vary), cell density was normalized to the TCPS cell density at P0 at confluence for each trial. The substrates were statistically compared at each passage using the Shapiro-Wilk normality test and one-way ANOVA (α set to 0.050) with Bonferroni post-hoc test (SigmaPlot Systat Software Inc.). The total number of cells at each passage was an estimate, calculated by assuming that each flask was split into 3 new flasks at each passage (though as noted only 1 flask was maintained).
Immunofluorescent Staining and Image Analysis
Cover slips used for the substrate screen were fixed and permeabilized in PBS containing 4% paraformaldehyde and 0.05% of Triton X-100 for 10 minutes. After fixation, samples were incubated with 1:200 dilution of DAPI (Life Technologies) and 1:100 dilutions of monoclonal mouse anti-ZO-1 (Life Technologies) and Alexa Fluor 633 conjugated phalloidin (Life Technologies) in PBS for 2 hours at 37°C. Samples were rinsed 3 times in PBS and incubated with 1:100 dilution of Alexa Fluor 555 goat anti-mouse secondary antibody for two hours at 37°C. Samples were rinsed 3 times in PBS and mounted using Pro-Long gold anti-fade reagent. Confocal microscopy was performed on a Zeiss LSM 700 confocal microscope. Samples used for the long-term expansion were fixed at P1 and P5 and then permeabilized and stained using one of two different protocols. To visualize fibronectin, samples were stained for the nucleus (DAPI) and ZO-1 as described for the cover slips with the addition of a 1:100 dilution of polyclonal rabbit anti-FN (Sigma-Aldrich) with goat anti-rabbit Alexa Fluor 488 secondary antibody. To visualize α-SMA, samples were stained for the nucleus (DAPI) and F-actin (phalloidin) as described for the cover slips with the addition of a 1:100 dilution of monoclonal mouse anti-α-SMA (Abcam, MA) with goat anti-mouse Alexa Fluor 488 secondary antibody. Samples were mounted using Pro-Long gold anti-fade reagent and imaged on a Zeiss LSM 700 laser scanning confocal microscope.
Quantitative image analysis was performed using a combination of ImageJ and Metamorph software. The percentage of cells expressing α-SMA was determined by using the multi-point selection tool in ImageJ to count the number of α-SMA positive cells and reporting this as a percentage relative to the total number of cells based on DAPI stained nuclei. Results for the three substrates were statistically analyzed at P1 and P5 using one-way ANOVA on the ranks with Tukey's pairwise comparison (SigmaPlot). The hexagonal shape factor (HSF) was calculated using quantitative morphology analysis of the ZO-1 at the cell-cell border and DAPI nuclear staining to verify the presence of the cells in each location. Metamorph (Molecular Devices) was used to detect the ZO-1 fluorescence and create a rendering of the outline of each cell in an image followed by manual touchup. From these outlines Metamorph calculated the cell area (A), perimeter (P) and HSF = (P2/A) − 13.856 for each cell57,58. Results for CE cells on the three substrates were statistically analyzed at P1 and P5 using a one-way ANOVA on the ranks with Dunn's pairwise comparison (SigmaPlot).
Tissue Engineered CE Monolayers
Collagen type I gels were fabricated by pipetting 200 μL of a 6 mg/mL collagen I solution (rat tail, BD Biosciences) onto a glass coverslip with a 20 mm diameter adhesive silicon ring used to control the shape of the gel. The gels were then placed in a 37°C, 5% CO2 incubator for 3 hours to evaporate excess water59. The gels were then removed and completely dried in a biohood before rehydrating in PBS and sterilization by UV treatment for 15 minutes. CE cells at P5 from each of the three substrates were seeded onto the collagen I gels at a density of 300,000 cells per gel, with 3 gels per condition. Cells were monitored for cell growth and morphology over a 48 hour day period using phase contrast microscopy. At 48 hours, all samples were fixed and permeabilized in PBS containing 4% paraformaldehyde and 0.05% of Triton X-100 for 10 minutes and stained for the nucleus (Nuc Blue, Life Technologies), ZO-1 and F-actin as described above. The cell density was calculated by counting the cells in the fluorescent images. Statistical analysis was performed using a one-way ANOVA (α set to 0.050) with Tukey pairwise comparison test to determine statistical significance.
Zhu, C. & Joyce, N. C. Proliferative response of corneal endothelial cells from young and older donors. Invest Ophth Vis Sci. 45, 1743–1751 (2004).
Joyce, N. C. Proliferative capacity of the corneal endothelium. Prog Retin Eye Res. 22, 359–389 (2003).
Joyce, N. C., Meklir, B., Joyce, S. J. & Zieske, J. D. Cell cycle protein expression and proliferative status in human corneal cells. Invest Ophth Vis Sci. 37, 645–655 (1996).
Joyce, N. C., Navon, S. E., Roy, S. & Zieske, J. D. Expression of cell cycle-associated proteins in human and rabbit corneal endothelium in situ. Invest Ophth Vis Sci. 37, 1566–1575 (1996).
Murphy, C., Alvarado, J., Juster, R. & Maglio, M. Prenatal and Postnatal Cellularity of the Human Corneal Endothelium - a Quantitative Histologic-Study. Invest Ophth Vis Sci. 25, 312–322 (1984).
Nucci, P., Brancato, R., Mets, M. B. & Shevell, S. K. Normal endothelial cell density range in childhood. Arch Ophthalmol. 108, 247–248 (1990).
Engelmann, K., Bednarz, J. & Valtink, M. Prospects for endothelial transplantation. Exp Eye Res. 78, 573–578 (2004).
Price, M. O. & Price, F. W., Jr Descemet membrane endothelial keratoplasty. Int Ophthalmol Clin. 50, 137–147 (2010).
Terry, M. A. & Ousley, P. J. Deep lamellar endothelial keratoplasty in the first United States patients: early clinical results. Cornea. 20, 239–243 (2001).
Terry, M. A. & Ousley, P. J. Endothelial replacement without surface corneal incisions or sutures: topography of the deep lamellar endothelial keratoplasty procedure. Cornea. 20, 14–18 (2001).
Melles, G. R., Lander, F., van Dooren, B. T., Pels, E. & Beekhuis, W. H. Preliminary clinical results of posterior lamellar keratoplasty through a sclerocorneal pocket incision. Ophthalmology. 107, 1850–1856; discussion 1857 (2000).
Faraj, L. A., Hashmani, K., Khatib, T., Al-Aqaba, M. & Dua, H. S. The changing face of corneal graft rejection. Br. J. Ophthalmol. 96, 1049–1050 (2012).
Wu, E. I., Ritterband, D. C., Yu, G., Shields, R. A. & Seedor, J. A. Graft rejection following descemet stripping automated endothelial keratoplasty: features, risk factors and outcomes. Am. J. Ophthalmol. 153, 949–957 e941 (2012).
Price, M. O. et al. Descemet's Stripping Automated Endothelial Keratoplasty Three-Year Graft and Endothelial Cell Survival Compared with Penetrating Keratoplasty. Ophthalmology. 120, 246–251 (2013).
Peh, G. S. L., Beuerman, R. W., Colman, A., Tan, D. T. & Mehta, J. S. Human Corneal Endothelial Cell Expansion for Corneal Endothelium Transplantation: An Overview. Transplantation. 91, 811–819 (2011).
Tan, D. T. H., Dart, J. K. G., Holland, E. J. & Kinoshita, S. Ophthalmology 3 Corneal transplantation. Lancet. 379, 1749–1761 (2012).
Zhu, Y. T., Chen, H. C., Chen, S. Y. & Tseng, S. C. G. Nuclear p120 catenin unlocks mitotic block of contact-inhibited human corneal endothelial monolayers without disrupting adherent junctions. J. Cell Sci. 125, 3636–3648 (2012).
Peh, G. S. L., Toh, K. P., Wu, F. Y., Tan, D. T. & Mehta, J. S. Cultivation of Human Corneal Endothelial Cells Isolated from Paired Donor Corneas. PLoS ONE. 6 (2011).
Peh, G. S. et al. Propagation of Human Corneal Endothelial Cells? A Novel Dual Media Approach. Cell Transplant. 10.3727/096368913X675719 (2013).
Chen, K. H., Azar, D. & Joyce, N. C. Transplantation of adult human corneal endothelium ex vivo: a morphologic study. Cornea 20, 731–737 (2001).
Gao, Y. et al. In vitro culture of human fetal corneal endothelial cells. Graef Arch Clin Exp. 249, 663–669 (2011).
Okumura, N. et al. Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops. Br J Ophthalmol. 95, 1006–1009 (2011).
Okumura, N. et al. Enhancement on primate corneal endothelial cell survival in vitro by a ROCK inhibitor. Invest Ophth Vis Sci. 50, 3680–3687 (2009).
Okumura, N. et al. ROCK Inhibitor Converts Corneal Endothelial Cells into a Phenotype Capable of Regenerating In Vivo Endothelial Tissue. Am J Pathol. 181, 268–277 (2012).
Kimoto, M., Shima, N., Yamaguchi, M., Amano, S. & Yamagami, S. Role of hepatocyte growth factor in promoting the growth of human corneal endothelial cells stimulated by L-ascorbic acid 2-phosphate. Invest Ophth Vis Sci. 53, 7583–7589 (2012).
Shima, N., Kimoto, M., Yamaguchi, M. & Yamagami, S. Increased proliferation and replicative lifespan of isolated human corneal endothelial cells with L-ascorbic acid 2-phosphate. Invest Ophth Vis Sci. 52, 8711–8717 (2011).
Miyata, K. et al. Effect of donor age on morphologic variation of cultured human corneal endothelial cells. Cornea. 20, 59–63 (2001).
Baum, J. L., Niedra, R., Davis, C. & Yue, B. Y. J. T. Mass-Culture of Human Corneal Endothelial-Cells. Arch Ophthalmol-Chic. 97, 1136–1140 (1979).
Yue, B. Y. J. T., Sugar, J., Gilboy, J. E. & Elvart, J. L. Growth of Human Corneal Endothelial-Cells in Culture. Invest Ophth Vis Sci. 30, 248–253 (1989).
Bednarz, J., Aboalchamat, B. & Engelmann, K. Characterization of immortalized human corneal endothelial cells. Invest Ophth Vis Sci. 41, S448–S448 (2000).
Bednarz, J., Teifel, M., Friedl, P. & Engelmann, K. Immortalization of human corneal endothelial cells using electroporation protocol optimized for human corneal endothelial and human retinal pigment epithelial cells. Acta Ophthalmol Scand. 78, 130–136 (2000).
Blake, D. A., Yu, H. N., Young, D. L. & Caldwell, D. R. Matrix stimulates the proliferation of human corneal endothelial cells in culture. Invest Ophth Vis Sci. 38, 1119–1129 (1997).
Yamaguchi, M. et al. Adhesion, migration and proliferation of cultured human corneal endothelial cells by laminin-5. Invest Ophth Vis Sci. 52, 679–684 (2011).
Choi, J. S. et al. In vitro evaluation of the interactions between human corneal endothelial cells and extracellular matrix proteins. Biomed Mater. 8 (2013).
Engler, A. J. et al. Embryonic cardiomyocytes beat best on a matrix with heart-like elasticity: scar-like rigidity inhibits beating. J. Cell Sci. 121, 3794–3802 (2008).
Engler, A. J., Sen, S., Sweeney, H. L. & Discher, D. E. Matrix elasticity directs stem cell lineage specification. Cell 126, 677–689 (2006).
Pelham, R. J. Jr & Wang, Y. Cell locomotion and focal adhesions are regulated by substrate flexibility. Proc Natl Acad Sci U S A. 94, 13661–13665 (1997).
Pelham, R. J. Jr & Wang, Y. L. Cell locomotion and focal adhesions are regulated by the mechanical properties of the substrate. Biol Bull. 194, 348–349; discussion 349–350 (1998).
Koizumi, N. et al. Cultivated corneal endothelial cell sheet transplantation in a primate model. Invest Ophth Vis Sci. 48, 4519–4526 (2007).
Proulx, S. et al. Tissue engineering of feline corneal endothelium using a devitalized human cornea as carrier. Tissue Eng Part A. 15, 1709–1718 (2009).
Proulx, S. et al. Transplantation of a tissue-engineered corneal endothelium reconstructed on a devitalized carrier in the feline model. Invest Ophth Vis Sci. 50, 2686–2694 (2009).
Palchesko, R. N., Zhang, L., Sun, Y. & Feinberg, A. W. Development of Polydimethylsiloxane Substrates with Tunable Elastic Modulus to Study Cell Mechanobiology in Muscle and Nerve. PLoS ONE. 7, e51499 (2012).
Kabosova, A. et al. Compositional differences between infant and adult human corneal basement membranes. Invest Ophth Vis Sci. 48, 4989–4999 (2007).
Last, J. A., Liliensiek, S. J., Nealey, P. F. & Murphy, C. J. Determining the mechanical properties of human corneal basement membranes with atomic force microscopy. J. Struct Biol. 167, 19–24 (2009).
Lee, J. G., Ko, M. K. & Kay, E. P. Endothelial mesenchymal transformation mediated by IL-1beta-induced FGF-2 in corneal endothelial cells. Exp Eye Res. 95, 35–39 (2012).
Kawaguchi, R. et al. Extracellular matrix components in a case of retrocorneal membrane associated with syphilitic interstitial keratitis. Cornea. 20, 100–103 (2001).
Chen, Q. K., Lee, K., Radisky, D. C. & Nelson, C. M. Extracellular matrix proteins regulate epithelial-mesenchymal transition in mammary epithelial cells. Differentiation. 86, 126–132 (2013).
Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin Invest. 119, 1420–1428 (2009).
Scanlon, C. S., Van Tubergen, E. A., Inglehart, R. C. & D'Silva, N. J. Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma. J. Dent Res. 92, 114–121 (2013).
Zeisberg, M. & Neilson, E. G. Biomarkers for epithelial-mesenchymal transitions. J. Clin Invest. 119, 1429–1437 (2009).
Ishizaki, M., Zhu, G., Haseba, T., Shafer, S. S. & Kao, W. W. Expression of collagen I, smooth muscle alpha-actin and vimentin during the healing of alkali-burned and lacerated corneas. Invest Ophth Vis Sci. 34, 3320–3328 (1993).
Okumura, N. et al. Inhibition of TGF-beta Signaling Enables Human Corneal Endothelial Cell Expansion In Vitro for Use in Regenerative Medicine. PLoS ONE. 8 (2013).
Zhu, Y. T. et al. Knockdown of Both p120 Catenin and Kaiso Promotes Expansion of Human Corneal Endothelial Monolayers via RhoA-ROCK-Noncanonical BMP-NF kappa B Pathway. Invest Ophth Vis Sci. 55, 1509–1518 (2014).
Li, W. et al. A novel method of isolation, preservation and expansion of human corneal endothelial cells. Invest Ophth Vis Sci. 48, 614–620 (2007).
Halliday, N. L. & Tomasek, J. J. Mechanical properties of the extracellular matrix influence fibronectin fibril assembly in vitro. Exp Cell Res. 217, 109–117 (1995).
Brown, A. C., Fiore, V. F., Sulchek, T. A. & Barker, T. H. Physical and chemical microenvironmental cues orthogonally control the degree and duration of fibrosis-associated epithelial-to-mesenchymal transitions. J. Patho.l 229, 25–35 (2013).
Behndig, A. Corneal endothelial integrity in aging mice lacking superoxide dismutase-1 and/or superoxide dismutase-3. Mol Vis. 14, 2025–2030 (2008).
Behndig, A., Karlsson, K., Brannstrom, T., Sentman, M. L. & Marklund, S. L. Corneal endothelial integrity in mice lacking extracellular superoxide dismutase. Invest Ophth Vis Sci. 42, 2784–2788 (2001).
Brown, R. A., Wiseman, M., Chuo, C. B., Cheema, U. & Nazhat, S. N. Ultrarapid engineering of biomimetic materials and tissues: Fabrication of nano- and microstructures by plastic compression. Adv Funct Mater. 15, 1762–1770 (2005).
This work was supported by an Ocular Tissue Engineering and Regenerative Medicine in the Ophthalmology (OTERO) postdoctoral fellowship from the Louis J. Fox Center for Vision Restoration at UPMC to R.N.P., the National Institutes of Health (NIH) Director's New Innovator Award Program, grant number DP2HL117750 to A.W.F. and NIH CORE Grant P30 EY008098, the Eye and Ear Foundation of Pittsburgh, PA and Unrestricted Grant from Research to Prevent Blindness to the Univ of Pittsburgh, Dept of Ophthalmology.
Yes, there is potential competing interest. Drs. Palchesko, Funderburgh and Feinberg are co-inventors on a filed patent application related to the expansion technology in this manuscript.
Electronic supplementary material
About this article
Cite this article
Palchesko, R., Lathrop, K., Funderburgh, J. et al. In Vitro Expansion of Corneal Endothelial Cells on Biomimetic Substrates. Sci Rep 5, 7955 (2015). https://doi.org/10.1038/srep07955
Advanced Functional Materials (2020)
Current Ophthalmology Reports (2020)
Experimental Eye Research (2020)
Designer Descemet Membranes Containing PDLLA and Functionalized Gelatins as Corneal Endothelial Scaffold
Advanced Healthcare Materials (2020)
ACS Biomaterials Science & Engineering (2020)